At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma
In Brief
A Phase 2 clinical trial evaluating Brentuximab Vedotin, Adriamycin, and 1 other intervention for Hodgkin Lymphoma. Completed, enrolled 34 participants across 2 sites.
Detailed Summary
Limited stage Hodgkin lymphoma is a highly curable disease, but standard treatment with ABVD chemotherapy and radiation can lead to late risks of secondary cancers, lung injury, heart injury, and others. This trial eliminates radiation therapy and reduces intensity of chemotherapy by incorporating the highly active FDA-approved targeted therapy brentuximab vedotin, an antibody-drug conjugate specifically against the lymphoma cells, combined with the standard chemotherapy drugs Adriamycin and Dacarbazine (AD).